HAE Acute Attack, Emergency Management

Emergency management of a confirmed or strongly suspected HAE acute attack. Routes by airway involvement, laryngeal/throat attacks require simultaneous on-demand therapy and airway preparation; non-airway attacks are treated early on-demand. Covers all five FDA-approved agents with dosing, FFP caveats, and the common error of giving antihistamines/corticosteroids instead of targeted therapy.

Evidence tier: Guideline-derived.

Decision points

  • Is the airway involved?

Do-not-miss pitfalls

  • Antihistamines, corticosteroids, and epinephrine do NOT reverse HAE attacks, the mechanism is bradykinin, not histamine. Giving these instead of targeted therapy is a sentinel error. Epinephrine may provide transient benefit in laryngeal attacks as a bridge only.
  • A laryngeal attack can progress from mild hoarseness to complete obstruction in hours. Initiate on-demand therapy AND prepare for difficult airway simultaneously, neither track waits for the other.
  • Every patient with a laryngeal attack must go to an emergency department even if they self-administered on-demand therapy, swelling can worsen before it improves.
  • Fresh frozen plasma (FFP) can WORSEN an HAE attack by supplying bradykinin-generating substrate (HMW kininogen, prekallikrein, factor XII). It is a last resort only when no approved on-demand agent is available, and only with airway protection ready.
  • Ecallantide carries a ~2% anaphylaxis risk and black-box warning, it must be administered by a healthcare professional, not self-administered.
  • Abdominal HAE attacks mimic a surgical abdomen (severe pain, vomiting, ascites visible on ultrasound), do not proceed to laparotomy without first treating for HAE.
  • An attack that does not respond to antihistamines/steroids is a diagnostic clue for HAE, do not interpret non-response as treatment failure; it is a pointer to the correct diagnosis.
  • Patients on long-term prophylaxis still need on-demand medication, prophylaxis reduces but does not eliminate attacks.

Evidence & citations

  1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. doi:10.1016/j.jaip.2020.08.046
  2. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema, The 2021 revision and update. Allergy. 2022;77(7):1961-1990. PMID 35006617

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.